{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:56:58Z","timestamp":1754161018477,"version":"3.41.2"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,28]]},"DOI":"10.7759\/cureus.88893","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:56:11Z","timestamp":1753703771000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study"],"prefix":"10.7759","author":[{"given":"Jimmy","family":"Joseph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Insights from the liraglutide clinical development program-the liraglutide effect and action in diabetes (LEAD) studies","volume":"121","author":"McGill JB","year":"2009","unstructured":"McGill JB. Insights from the liraglutide clinical development program-the liraglutide effect and action in diabetes (LEAD) studies. Postgrad Med. 2009, 121:16-25. https:\/\/pubmed.ncbi.nlm.nih.gov\/19491536\/","journal-title":"Postgrad Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114547358","article-title":"The effect of liraglutide on endothelial function in patients with type 2 diabetes","volume":"11","author":"Nandy D","year":"2014","unstructured":"Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB, Basu A. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res. 2014, 11:419-30. 10.1177\/1479164114547358","journal-title":"Diab Vasc Dis Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher JR","year":"2014","unstructured":"Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014, 114:1788-803. 10.1161\/CIRCRESAHA.114.301958","journal-title":"Circ Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00473.2012","article-title":"Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment","volume":"304","author":"Dong Z","year":"2013","unstructured":"Dong Z, Chai W, Wang W, Zhao L, Fu Z, Cao W, Liu Z. Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab. 2013, 304:E222-8. 10.1152\/ajpendo.00473.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller JP","year":"2004","unstructured":"Gutzwiller JP, Tschopp S, Bock A, et al.. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004, 89:3055-61. 10.1210\/jc.2003-031403","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov J","year":"2013","unstructured":"Skov J, Dejgaard A, Fr\u00f8ki\u00e6r J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013, 98:E664-71. 10.1210\/jc.2012-3855","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Kristensen SL","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019, 7:P776-85. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393228-sustained-effects-of-glucagon-like-peptide-1-glp-1-agonists-on-blood-pressure-in-obesity-and-type-2-diabetes-a-longitudinal-case-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:56:11Z","timestamp":1753703771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393228-sustained-effects-of-glucagon-like-peptide-1-glp-1-agonists-on-blood-pressure-in-obesity-and-type-2-diabetes-a-longitudinal-case-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.88893","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}